Experimental Drug Zorevunersen Shows Up to 91% Seizure Reduction in Children with Dravet Syndrome
核心洞察
A new experimental drug called zorevunersen demonstrated up to 91% reduction in seizures (搜索) among children with Dravet syndrome (搜索) in an international clinical trial led by UCL and Great Ormond Street Hospital (搜索).
The gene therapy treatment works by increasing protein levels from the healthy SCN1A (搜索) gene copy to restore proper nerve cell function in patients with this devastating genetic epilepsy (搜索) condition.
Results from 81 children aged 2-18 showed the drug is safe and well-tolerated, with patients experiencing improved quality of life and cognitive function over a three-year period.
A new experimental treatment for children with Dravet syndrome (搜索) has demonstrated remarkable efficacy in reducing seizures (搜索) by up to 91%, offering unprecedented hope for families affected by this devastating genetic form of epilepsy (搜索). The findings from an international clinical trial led by University College London (UCL) and Great Ormond Street Hospital (搜索) were published in The New England Journal of Medicine.
Gene Therapy Approach Targets Root Cause
Zorevunersen, developed by Stoke Therapeutics in collaboration with Biogen, represents a breakthrough in treating the underlying genetic cause of Dravet syndrome (搜索). The condition affects approximately one in every 15,000 babies born and is caused by mutations in the SCN1A (搜索) gene, which normally produces sodium channels (搜索) essential for proper brain cell communication.
"Humans typically have two copies of the SCN1A (搜索) gene and in most people with Dravet syndrome (搜索), one copy of this gene doesn't produce enough of a protein for their nerve cells to function properly," explained the research team. Zorevunersen works by increasing the levels of protein produced by the healthy SCN1A gene copy, aiming to restore proper nerve-cell function.
Clinical Trial Results Show Dramatic Improvements
The study involved 81 children aged two to 18 years across the UK and US, who had an average of 17 seizures (搜索) per month before treatment began. Patients received up to 70mg of zorevunersen via lumbar puncture, administered as either a single dose or with additional doses two to three months later over a six-month period.
Of the initial participants, 75 continued in extension studies, receiving the drug every four months. Patients who received the 70mg dose experienced seizure reductions ranging from 59% to 91% over the first 20 months of the extension studies compared to their pre-trial seizure frequency.
The treatment's impact extended beyond seizure control. "The results also show, for the first time, the potential to reduce the impact of the condition on a child's mental processes and behaviour," according to the published findings. Children's quality of life improved over the three-year study period, with most side effects being mild.
Transformative Impact on Patient Lives
Eight-year-old Freddie Truelove from Huddersfield exemplifies the treatment's potential. After starting zorevunersen in 2021, he went from experiencing more than a dozen nighttime seizures (搜索) to just one or two brief seizures lasting only seconds every three to five days.
"The trial has completely changed our lives. We now have a life we didn't ever think was possible and most importantly it's a life that Freddie can enjoy," said his mother Lauren. She described how Freddie has since been able to climb mountains, walk with dogs around lakes, and even go skiing - activities previously impossible due to his condition.
Addressing Critical Unmet Medical Need
Dravet syndrome (搜索) represents one of the most challenging forms of childhood epilepsy (搜索), causing frequent, hard-to-control seizures (搜索) alongside long-term neurodevelopmental impairment, feeding difficulties, movement problems, and carrying a high risk of premature death. Current treatments fail to control seizures in most patients, and no approved medicines address the condition's cognitive and behavioral impacts.
Lead author Professor Helen Cross, Director and Professor of Childhood Epilepsy (搜索) at the UCL Institute of Child Health and Honorary Consultant in Paediatric Neurology at Great Ormond Street Hospital (搜索), emphasized the significance of these results: "I regularly see patients with hard-to-treat genetic epilepsies with impacts that go beyond seizures (搜索) and it's heart-breaking when treatment options are limited. This new treatment could help children with Dravet syndrome (搜索) lead much healthier and happier lives."
Path Forward to Regulatory Approval
The published data represent initial studies designed primarily to evaluate safety and tolerability, while also assessing effects on seizures (搜索), cognition, behavior, and quality of life. A Phase Three study is currently underway to further evaluate the treatment's effectiveness.
Nineteen of the trial participants were treated at UK hospitals including Great Ormond Street Hospital (搜索), Sheffield Children's Hospital, Evelina London Children's Hospital, and The Royal Hospital for Children in Glasgow. The trial was conducted at the National Institute of Health and Care Research's Clinical Research Facility at GOSH.
Galia Wilson, Chair of Trustees at Dravet Syndrome (搜索) UK, expressed optimism about the results: "We regularly see the devastating impact that this condition has on the lives of families. That's why we're so thrilled about these latest results from the initial zorevunersen clinical trials. We're now looking forward to the Phase Three clinical trials taking place to see if the early promise we see here will translate into real hope for all those families currently affected by Dravet Syndrome."